A. Olayide, Aremu Isiaka, R. Ganiyu, Olatoke Samuel, Akande Halimat, Olasehinde Olalekan, Olaogun Julius, Romanoff Anya
{"title":"尼日利亚的乳腺癌治疗和结果:系统回顾与元分析","authors":"A. Olayide, Aremu Isiaka, R. Ganiyu, Olatoke Samuel, Akande Halimat, Olasehinde Olalekan, Olaogun Julius, Romanoff Anya","doi":"10.31557/apjcc.2023.8.3.591-598","DOIUrl":null,"url":null,"abstract":"Background: Nigeria has one of the highest age-standardized breast cancer (BC) mortality rates globally and the highest in Africa. Late presentation and diagnosis have been studied extensively as causes of high BC morbidity and mortality, while treatment and outcomes are under-reported. We aggregated data on BC treatment and outcomes in Nigeria to identify gaps in research, challenges, and potential targets for future interventions.Methods: Articles on female BC management in Nigeria published between 2011 and 2021 were reviewed for the prevalence of different treatment modalities and outcomes. The meta-analytical procedure was a random effect model. Results: We identified 15 articles that reported on the treatment and outcomes of 3857 BC patients. The most prevalent treatment modality was chemotherapy alone. The probability of receiving each treatment modality was 85% (95% CI 66-97) for chemotherapy, 62% (95% CI 51-73) for surgery, and 31% (95% CI 8-59) for radiotherapy. Multimodality treatment, including chemotherapy, surgery, and radiation, was administered to 24% (95% CI 10-43) of patients. In studies with available data, nearly half of patients who initiated chemotherapy did not complete the recommended number of doses or received treatments at irregular intervals. The radiotherapy utilization was five times higher when patients received treatment in centers with radiation facilities. Overall survival estimates were 80% at one year, 43% at two years, and 32% at five years. Patients with early-stage (AJCC I/II) disease survived longer, with a 5-year survival difference of 32% compared to patients with late-stage (AJCC III/IV) disease. Patients receiving multimodality therapy survived longer. Three-year survival for patients who received chemotherapy, surgery and radiotherapy was 68%. Whereas it was 43% in patients who received chemotherapy and surgery only. Conclusion: Improving access to complete systemic therapy, surgery, and radiation for breast cancer patients in Nigeria is imperative and should be the target of future interventions.","PeriodicalId":502165,"journal":{"name":"Asian Pacific Journal of Cancer Care","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Breast Cancer Treatment and Outcomes in Nigeria: A Systematic Review and Meta-analysis\",\"authors\":\"A. Olayide, Aremu Isiaka, R. Ganiyu, Olatoke Samuel, Akande Halimat, Olasehinde Olalekan, Olaogun Julius, Romanoff Anya\",\"doi\":\"10.31557/apjcc.2023.8.3.591-598\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Nigeria has one of the highest age-standardized breast cancer (BC) mortality rates globally and the highest in Africa. Late presentation and diagnosis have been studied extensively as causes of high BC morbidity and mortality, while treatment and outcomes are under-reported. We aggregated data on BC treatment and outcomes in Nigeria to identify gaps in research, challenges, and potential targets for future interventions.Methods: Articles on female BC management in Nigeria published between 2011 and 2021 were reviewed for the prevalence of different treatment modalities and outcomes. The meta-analytical procedure was a random effect model. Results: We identified 15 articles that reported on the treatment and outcomes of 3857 BC patients. The most prevalent treatment modality was chemotherapy alone. The probability of receiving each treatment modality was 85% (95% CI 66-97) for chemotherapy, 62% (95% CI 51-73) for surgery, and 31% (95% CI 8-59) for radiotherapy. Multimodality treatment, including chemotherapy, surgery, and radiation, was administered to 24% (95% CI 10-43) of patients. In studies with available data, nearly half of patients who initiated chemotherapy did not complete the recommended number of doses or received treatments at irregular intervals. The radiotherapy utilization was five times higher when patients received treatment in centers with radiation facilities. Overall survival estimates were 80% at one year, 43% at two years, and 32% at five years. Patients with early-stage (AJCC I/II) disease survived longer, with a 5-year survival difference of 32% compared to patients with late-stage (AJCC III/IV) disease. Patients receiving multimodality therapy survived longer. Three-year survival for patients who received chemotherapy, surgery and radiotherapy was 68%. Whereas it was 43% in patients who received chemotherapy and surgery only. Conclusion: Improving access to complete systemic therapy, surgery, and radiation for breast cancer patients in Nigeria is imperative and should be the target of future interventions.\",\"PeriodicalId\":502165,\"journal\":{\"name\":\"Asian Pacific Journal of Cancer Care\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Pacific Journal of Cancer Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31557/apjcc.2023.8.3.591-598\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/apjcc.2023.8.3.591-598","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:尼日利亚是全球年龄标准化乳腺癌(BC)死亡率最高的国家之一,也是非洲死亡率最高的国家。作为乳腺癌高发病率和高死亡率的原因,晚诊和诊断已被广泛研究,而治疗和结果却未得到充分报道。我们汇总了尼日利亚有关乳腺癌治疗和结果的数据,以确定研究中的差距、挑战以及未来干预的潜在目标:我们对 2011 年至 2021 年间发表的有关尼日利亚女性 BC 管理的文章进行了审查,以了解不同治疗方式和结果的流行程度。荟萃分析程序采用随机效应模型。结果:我们确定了 15 篇文章,报告了 3857 名 BC 患者的治疗情况和结果。最普遍的治疗方式是单纯化疗。接受每种治疗方式的概率分别为:化疗 85% (95% CI 66-97),手术 62% (95% CI 51-73),放疗 31% (95% CI 8-59)。24%(95% CI 10-43)的患者接受了包括化疗、手术和放疗在内的多模式治疗。在有数据可查的研究中,近一半开始接受化疗的患者没有完成推荐的剂量,或接受治疗的时间间隔不规律。在有放射设施的中心接受治疗的患者,放射治疗的使用率要高出五倍。总生存率估计为:一年 80%,两年 43%,五年 32%。早期(AJCC I/II期)患者的存活时间更长,与晚期(AJCC III/IV期)患者相比,5年存活率相差32%。接受多模式疗法的患者存活时间更长。接受化疗、手术和放疗的患者三年存活率为 68%。而仅接受化疗和手术的患者的三年生存率为 43%。结论改善尼日利亚乳腺癌患者接受全面系统治疗、手术和放疗的机会势在必行,应成为未来干预措施的目标。
Breast Cancer Treatment and Outcomes in Nigeria: A Systematic Review and Meta-analysis
Background: Nigeria has one of the highest age-standardized breast cancer (BC) mortality rates globally and the highest in Africa. Late presentation and diagnosis have been studied extensively as causes of high BC morbidity and mortality, while treatment and outcomes are under-reported. We aggregated data on BC treatment and outcomes in Nigeria to identify gaps in research, challenges, and potential targets for future interventions.Methods: Articles on female BC management in Nigeria published between 2011 and 2021 were reviewed for the prevalence of different treatment modalities and outcomes. The meta-analytical procedure was a random effect model. Results: We identified 15 articles that reported on the treatment and outcomes of 3857 BC patients. The most prevalent treatment modality was chemotherapy alone. The probability of receiving each treatment modality was 85% (95% CI 66-97) for chemotherapy, 62% (95% CI 51-73) for surgery, and 31% (95% CI 8-59) for radiotherapy. Multimodality treatment, including chemotherapy, surgery, and radiation, was administered to 24% (95% CI 10-43) of patients. In studies with available data, nearly half of patients who initiated chemotherapy did not complete the recommended number of doses or received treatments at irregular intervals. The radiotherapy utilization was five times higher when patients received treatment in centers with radiation facilities. Overall survival estimates were 80% at one year, 43% at two years, and 32% at five years. Patients with early-stage (AJCC I/II) disease survived longer, with a 5-year survival difference of 32% compared to patients with late-stage (AJCC III/IV) disease. Patients receiving multimodality therapy survived longer. Three-year survival for patients who received chemotherapy, surgery and radiotherapy was 68%. Whereas it was 43% in patients who received chemotherapy and surgery only. Conclusion: Improving access to complete systemic therapy, surgery, and radiation for breast cancer patients in Nigeria is imperative and should be the target of future interventions.